The role of intensive antiplatelet therapy for prevention of vascular events in patients with atrial fibrillation remains controversial.
This report from Garza et al describes improved outcomes in out-of-hospital cardiac arrest victims after a cardiopulmonary resuscitation (CPR) protocol change by the emergency medical services (EMS) system in Kansas City, MO.
The differential diagnosis of acute chest pain includes three entities that can be lethal if missed: myocardial infarction (MI), pulmonary embolus, and aortic dissection.
Six years ago, Wild and Law, two British physicians, proposed that a single pill with multiple active components could profoundly reduce cardiac risk (CV).
Although it is well known that incessant atrial tachyarrhythmias can cause left ventricular (LV) dysfunction, little is known about focal atrial tachycardia and LV dysfunction.
After acute coronary syndromes (ACS), re-currence of ischemia is a harbinger of worse prognosis.
New markers for a variety of diseases have recently received considerable attention, specifically B-type natriuretic peptide (BNP), N-terminal-pro-BNP, C-reactive protein, or CRP, and CRP-hs (high sensitivity). Levels of these compounds are useful guides in assessing the severity of important medical conditions, such as congestive heart failure and acute myocardial infarction chest pain.
Syncope is commonly accepted to be a danger sign in patients with hypertrophic cardiomyopathy (HCM). In this paper, Spirito et al report data from a registry of 1,511 patients with HCM who have been followed longitudinally at four institutions.
It has been postulated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II-receptor blockers (ARBs) decrease the risk of developing atrial fibrillation both indirectly by better control of hypertension and heart failure and directly by effects on fibrosis,
NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.
